In a report released on April 15, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Dexcom (DXCM – Research Report), with a price target of $165.00. The company’s shares closed yesterday at $136.52.
Singh Chadha covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Boston Scientific, and Abbott Labs. According to TipRanks, Singh Chadha has an average return of -0.4% and a 42.05% success rate on recommended stocks.
Dexcom has an analyst consensus of Strong Buy, with a price target consensus of $154.29, a 13.02% upside from current levels. In a report released on April 15, BTIG also maintained a Buy rating on the stock with a $156.00 price target.
Based on Dexcom’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.03 billion and a net profit of $256.3 million. In comparison, last year the company earned a revenue of $815.2 million and had a net profit of $91.8 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dexcom (DXCM) Company Description:
California-based DexCom, Inc. is a medical device manufacturing company. The company designs, develops and focuses on commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes. Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share.
Read More on DXCM:
